An antibody–drug conjugate targeting Nectin-4 (PVRL4). The monoclonal antibody binds Nectin-4 on tumor cells, is internalized, and releases an intracellular cytotoxic payload to kill the cancer cell; Fc-mediated effector functions may also contribute. Evaluated in advanced solid tumors including urothelial cancer, triple-negative breast cancer, and cervical cancer.
Monoclonal antibody targets Nectin-4 (PVRL4) on tumor cells, is internalized, and releases a tubulin-inhibiting cytotoxic payload (AP052), leading to inhibition of microtubule polymerization, G2/M arrest, and apoptosis in Nectin-4–expressing cells; Fc-mediated effector functions may also contribute.
ADC binds Nectin-4 on tumor cells, is internalized, and releases a tubulin-inhibiting payload (AP052) that disrupts microtubules, causing G2/M arrest and apoptosis; Fc-mediated effector functions (e.g., ADCC/CDC) may also contribute.
Investigational tetra-specific (multispecific) antibody biologic given by weekly IV infusion for relapsed/refractory B-cell malignancies (CLL/SLL and other NHL); designed to bind multiple antigens to enhance immune-mediated killing and reduce antigen escape.
Tetra-specific T‑cell–engaging antibody that binds ROR1 on tumor cells and CD3 on T cells to redirect cytotoxic T lymphocytes, while simultaneously blocking PD-L1 to relieve PD-1–mediated inhibition and agonizing 4-1BB to provide costimulation. The combined actions enhance T-cell activation and CTL-mediated lysis of ROR1+ malignant B cells and help mitigate antigen escape.
T-cell redirected cytotoxicity: the tetra-specific engager binds ROR1 on tumor cells and CD3 on T cells, provides 4-1BB costimulation and blocks PD-L1, activating CTLs to kill ROR1+ cells via perforin/granzyme-mediated lysis.
TROP-2–directed antibody–drug conjugate that delivers SN-38 (topoisomerase I inhibitor) to TROP-2–expressing tumor cells.
TROP-2–directed antibody–drug conjugate in which a humanized anti–TROP-2 monoclonal antibody (hRS7) delivers SN-38 (topoisomerase I inhibitor) to TROP-2–expressing tumor cells. Binding triggers internalization and linker cleavage to release SN-38, which stabilizes topoisomerase I–DNA complexes, causing DNA breaks, blocking replication, and inducing apoptosis.
The ADC binds TROP-2, is internalized, and releases SN-38 (topoisomerase I inhibitor) inside the cell, causing DNA damage and apoptosis.
Anti-CD79b antibody-drug conjugate that delivers MMAE to CD79b-positive B cells, disrupting microtubules and inducing apoptosis.
Anti-CD79b monoclonal antibody linked via a protease-cleavable linker to the microtubule inhibitor MMAE; after binding CD79b on B cells and internalization, MMAE is released to inhibit tubulin polymerization, causing G2/M arrest and apoptosis in CD79b-positive malignant B cells.
ADC binds CD79b on B cells, is internalized, linker is cleaved, and MMAE is released to inhibit tubulin polymerization, causing G2/M arrest and apoptosis of CD79b-positive cells.